Haleos Labs Limited (NSEI: HALEOSLABS)
Health Care · Pharmaceuticals · IN
Rs1,465.00
-1.31% today · +31.6% 1Y
Haleos Labs Limited (NSEI: HALEOSLABS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $46.29M and employs 592 people.
Over the last twelve months the share price has gained 31.6%, trading between 1.08K and 1.77K.
Tweenvest scores Haleos Labs Limited across four factors: quality 65/100, value 38/100, growth 2/100, dividend 38/100. Its strongest factor is quality.
HALEOSLABS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.29M
- Revenue (TTM)
- $34.29M
- P/E
- 28.03
- EPS
- 52.26
- Dividend yield
- 0.10%
- Beta (5Y)
- 0.32
- 52-week high
- Rs1,774.00
- 52-week low
- Rs1,076.10
- Avg volume (3M)
- —
- Shares outstanding
- 3.02M
- Employees
- 592
- Next earnings
- —
About Haleos Labs Limited
Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applications, providing treatments for conditions such as ulcers, migraines, hypertension, and erectile dysfunction. Additionally, the company develops products for cancer, fungal infections, obesity, nausea, depression, parasitic infestations, various infectious diseases, gout, convulsions, viral ailments, and anesthesia. They also supply ingredients for antihistamines, diuretics, hair loss treatments, and ophthalmic preparations. A significant portion of their manufactured goods is destined for international markets. Established in 1990 and headquartered in Hyderabad, India, the firm was formerly known as SMS Lifesciences India Limited and is scheduled to officially adopt its current name, Haleos Labs Limited, in August 2025.
- Founded
- 1990
- Listed since
- Aug 17, 2017
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,262.50 | +0.57% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.94 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | 0.00% |
| Roche Holding AGSWX: ROP | $373.91B | CHF369.90 | -1.52% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £120.80 | -1.31% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.